246 related articles for article (PubMed ID: 26277433)
61. VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02).
Feliu J; Garcia-Carbonero R; Capdevila J; Guasch I; Alonso-Orduna V; Lopez C; Garcia-Alfonso P; Castanon C; Sevilla I; Cerezo L; Conill C; Quintana-Angel B; Sanchez ME; Ghanem I; Martin-Richard M; Lopez-Gomez M; Leon A; Caro M; Fernandez T; Maurel J
Cancer Med; 2020 Feb; 9(3):1008-1016. PubMed ID: 31851776
[TBL] [Abstract][Full Text] [Related]
62. [Brachytherapy for anal cancers].
Pommier P; Mirabel X; Hannoun-Lévi JM; Malet C; Gérard JP; Peiffert D
Cancer Radiother; 2013 Apr; 17(2):143-50. PubMed ID: 23582604
[TBL] [Abstract][Full Text] [Related]
63. A phase II study of concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C for squamous cell carcinoma of the anal canal (the JROSG 10-2 trial).
Murofushi KN; Itasaka S; Shimokawa M; Murakami Y; Yamamoto T; Nishimura Y; Kudo S; Sakamoto T; Ariga T; Ogo E; Taguchi K; Jingu K; Ogawa K
J Radiat Res; 2023 Jan; 64(1):154-161. PubMed ID: 36280895
[TBL] [Abstract][Full Text] [Related]
64. Intensity-modulated Radiotherapy for Anal Cancer: Dose-Volume Relationship of Acute Gastrointestinal Toxicity and Disease Outcomes.
Ng M; Ho H; Skelton J; Guerrieri M; Guiney M; Chao M; Blakey D; Macleod C; Amor H; Subramanian B; Melven L
Clin Oncol (R Coll Radiol); 2018 Oct; 30(10):634-641. PubMed ID: 30049649
[TBL] [Abstract][Full Text] [Related]
65. Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index.
Hung A; Crane C; Delclos M; Ballo M; Ajani J; Lin E; Feig B; Skibber J; Janjan N
Cancer; 2003 Mar; 97(5):1195-202. PubMed ID: 12599225
[TBL] [Abstract][Full Text] [Related]
66. EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer.
Glynne-Jones R; Meadows H; Wan S; Gollins S; Leslie M; Levine E; McDonald AC; Myint S; Samuel L; Sebag-Montefiore D;
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):119-26. PubMed ID: 18472366
[TBL] [Abstract][Full Text] [Related]
67. [A Case of Perianal Squamous Cell Carcinoma with Left Inguinal Lymph Node Metastasis That Showed a Complete Response More Than Five Years after Chemotherapy and Concomitant Proton Beam Therapy].
Suzuki N; Azami A; Todate Y; Tada T; Waragai M; Honda M; Sato A; Takano Y; Abe T; Nakamura T; Teranishi Y
Gan To Kagaku Ryoho; 2017 Jun; 44(6):525-528. PubMed ID: 28698447
[TBL] [Abstract][Full Text] [Related]
68. Predictors of Radiation Therapy-Related Gastrointestinal Toxicity From Anal Cancer Dose-Painted Intensity Modulated Radiation Therapy: Secondary Analysis of NRG Oncology RTOG 0529.
Olsen JR; Moughan J; Myerson R; Abitbol A; Doncals DE; Johnson D; Schefter TE; Chen Y; Fisher B; Michalski J; Narayan S; Chang A; Crane CH; Kachnic L
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):400-408. PubMed ID: 28463160
[TBL] [Abstract][Full Text] [Related]
69. Inguinal lymph node recurrence in the untreated groin of patients with anal carcinoma.
Blinde SE; Schasfoort R; Mens JW; Verhoef C; Olofsen M; Nuyttens JJ
Dis Colon Rectum; 2014 May; 57(5):578-84. PubMed ID: 24819097
[TBL] [Abstract][Full Text] [Related]
70. Long-Term Outcomes of NRG Oncology/RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Anal Canal Cancer.
Kachnic LA; Winter KA; Myerson RJ; Goodyear MD; Abitbol AA; Streeter OE; Augspurger ME; Schefter TE; Katz AW; Fisher BJ; Henke LE; Narayan S; Crane CH
Int J Radiat Oncol Biol Phys; 2022 Jan; 112(1):146-157. PubMed ID: 34400269
[TBL] [Abstract][Full Text] [Related]
71. [A case of effective chemoradiotherapy using S-1 and CDDP for left inguinal lymph node metastasis of anal canal carcinoma].
Kuga Y; Tanaka T; Arita M; Usui Y; Okanobu H; Numata Y; Miwata T; Yoshimi S; Murakami E; Moriya T; Ohya T; Nishida T
Gan To Kagaku Ryoho; 2009 Nov; 36(11):1923-5. PubMed ID: 19920402
[TBL] [Abstract][Full Text] [Related]
72. Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2).
Higuchi K; Komori S; Tanabe S; Katada C; Azuma M; Ishiyama H; Sasaki T; Ishido K; Katada N; Hayakawa K; Koizumi W;
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):872-9. PubMed ID: 24867539
[TBL] [Abstract][Full Text] [Related]
73. Efficacy and safety of helical tomotherapy with daily image guidance in anal canal cancer patients.
De Bari B; Jumeau R; Bouchaab H; Vallet V; Matzinger O; Troussier I; Mirimanoff RO; Wagner AD; Hanhloser D; Bourhis J; Ozsahin EM
Acta Oncol; 2016 Jun; 55(6):767-73. PubMed ID: 27034083
[TBL] [Abstract][Full Text] [Related]
74. Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial.
Gunderson LL; Moughan J; Ajani JA; Pedersen JE; Winter KA; Benson AB; Thomas CR; Mayer RJ; Haddock MG; Rich TA; Willett CG
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):638-45. PubMed ID: 24035327
[TBL] [Abstract][Full Text] [Related]
75. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
76. Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series.
Franco P; Mistrangelo M; Arcadipane F; Munoz F; Sciacero P; Spadi R; Migliaccio F; Angelini V; Bombaci S; Rondi N; Numico G; Ragona R; Cassoni P; Morino M; Racca P; Ricardi U
Cancer Invest; 2015 Jul; 33(6):259-66. PubMed ID: 25950188
[TBL] [Abstract][Full Text] [Related]
77. Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer--evidence from a phase II trial.
Colaco R; Sheikh H; Lorigan P; Blackhall F; Hulse P; Califano R; Ashcroft L; Taylor P; Thatcher N; Faivre-Finn C
Lung Cancer; 2012 Apr; 76(1):72-7. PubMed ID: 22014897
[TBL] [Abstract][Full Text] [Related]
78. Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC).
Rivin Del Campo E; Matzinger O; Haustermans K; Peiffert D; Glynne-Jones R; Winter KA; Konski AA; Ajani JA; Bosset JF; Hannoun-Levi JM; Puyraveau M; Chakravarthy AB; Meadows H; Northover J; Collette L; Christiaens M; Maingon P
Eur J Cancer; 2019 Nov; 121():130-143. PubMed ID: 31574418
[TBL] [Abstract][Full Text] [Related]
79. Capecitabine With Mitomycin Reduces Acute Hematologic Toxicity and Treatment Delays in Patients Undergoing Definitive Chemoradiation Using Intensity Modulated Radiation Therapy for Anal Cancer.
Goodman KA; Julie D; Cercek A; Cambridge L; Woo KM; Zhang Z; Wu AJ; Reidy DL; Segal NH; Stadler ZK; Saltz LB
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1087-1095. PubMed ID: 28721892
[TBL] [Abstract][Full Text] [Related]
80. [New technologies in the diagnosis and treatment of patients with squamous cell carcinoma of the anal canal].
Malikhov AG; Barsukov IuA; Malikhova OA; Ungiadze GV; Timofeev IuM; Perfil'ev IB
Eksp Klin Gastroenterol; 2011; (10):73-7. PubMed ID: 22629704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
